Invitrogen Plans to Sell, Discontinue Some Minor Product Lines; Q1 Sales Fall Short of Expectations | GenomeWeb

After adding several new businesses and products through acquisitions over the last couple of years, Invitrogen is now considering selling off or discontinuing some 'minor' yet undisclosed product lines or business units, the firm said this week.

The firm is not disclosing which products or businesses are being considered for divestiture, and a company spokesperson told BioCommerce Week that the process is the natural result of integrating many pieces into the company over the past two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.